Purchase this article with an account.
Rieko Higashida, Yutaka Imamura, Atsushi Ishikawa, Yorihisa Tsutsumi, Yoshikazu Ichikawa, Takeshi Wakakuri, Masahiro Ishida; Intravitreal injection of bevacizumab for diabetic macula edema: morphological and functional outcomes at 1 day after injection.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1764. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate and compare the visual and anatomical outcomes in eyes with diabetic macular edema (DME) at 1 day and 1 week after injection of intravitreal bevacizumab.
A retrospective, consecutive case series identified 21 consecutive patients with DME undergoing intravitreal injection of bevacizumab. Optical coherence tomography images were taken at the day of injection and 1-day and 1 week after injection. Retinal thickness at fovea and visual acuity were monitored before and after injection.
The mean age of patients was 65.1 years old (10 females). Retinal thickness at fovea was 490 ± 169 µm before injection, and was 442 ± 162 µm and 335 ± 148 µm at 1 day and 1 week after injection. (Student t test, P=0.001 and 0.004, respectively) Visual acuity (logMAR) was 0.616±0.344 before injection and 0.682±0.413 and 0.425±0.237 at 1 day and 1 week after injection. (P=0.567 and 0.063, respectively)
Resolution of intraretinal fluids was observed at 1 day postoperatively, however at least 1 week is needed so that large amounts of fluids are absorbed in DME. Significant improvement of vision was not observed at 1 day and 1 week after injection. Intraretinal fluids seem to disappear more slowly in DME than those in retinal vein occulusion after intravitreal injection of bevacizumab (Ishikawa A, 2013 ARVO abstract).
This PDF is available to Subscribers Only